Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Intensive Care MedicineJun 8, 2026
International evidence-based recommendations for point-of-care lung ultrasound

Clinical Context

We think this has broad domain relevance to ATA Thyroid Recurrence Risk.

CancerJun 8, 2026
Clinicopathologic characteristics of early‐onset breast cancer among unselected young Black women

Clinical Context

We think this has broad domain relevance to ATA Thyroid Recurrence Risk.

DiabetologiaJun 5, 2026
Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes

Clinical Context

We think this has broad domain relevance to ATA Thyroid Recurrence Risk.

ATA Thyroid Risk

ATA THYROIDRisk Stratification for Differentiated Cancer

Clinical Risk Tier

Note: ATA risk is distinct from AJCC staging. ATA risk predicts the likelihood of recurrence, while AJCC predicts the likelihood of mortality.

Risk Profile

Low

Recurrence Outlook

Low risk of structural recurrence (< 5%). Routine follow-up with thyroglobulin monitoring is standard.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Patients with papillary or follicular thyroid cancer after total thyroidectomy.
Used to determine the necessity and dosage of Radioactive Iodine (RAI) ablation.
Guides the intensity of follow-up (frequency of ultrasound and thyroglobulin monitoring).

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the CTCAE v5.0 or the Ecog Status to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

CTCAE v5.0
HCT-CI
TNM 9th Ed
DIPSS-Plus
TNM 8th
TNM 9th
ISUP Grade Groups
iwCLL 2018 Response
PERCIST 2.0
RECIST 1.1
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.